23:45 , Jul 18, 2019 |  BC Extra  |  Financial News

Kronos parlays diverse pipeline into $105M series A

The speed at which Kronos assembled a broad small molecule platform against hard-to-target hormone receptors, transcription factors and E3 ligases enabled it to raise a $105 million A round led by seed investors Vida Ventures...
19:37 , Sep 20, 2018 |  BC Innovations  |  Emerging Company Profile

Recalcitrant Targets

With a fresh take on small molecule microarray technology, Kronos Bio Inc. aims to identify small molecule inhibitors of oncology targets considered undruggable, starting with a splice variant of the androgen receptor expressed in metastatic...
17:29 , Sep 14, 2018 |  BC Week In Review  |  Financial News

Epic raises $52M series E

Epic Sciences Inc. (San Diego, Calif.) raised $52 million in a series E round led by Blue Ox Healthcare Partners. Fellow new investors Deerfield Management and Varian Medical Systems Inc. (NYSE:VAR) joined existing investors Altos...
18:57 , May 30, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer In vitro , cell culture and mouse studies suggest inhibiting the DNAJ/Hsp70 chaperone axis could help treat castration-resistant prostate cancer (CRPC). Screening of a library of chalcone analogs and testing in cell-based...
03:45 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Meeting the burden

A major theme at this year’s AACR is the abundance of preclinical discovery driven by molecular signatures in patient samples, suggesting the research community is heeding the call for studies better grounded in human data,...
13:53 , Oct 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Prostate cancer Cell culture and mouse studies suggest an N -carboxyaniline-based selective androgen receptor degrader (SARD) could help treat castration-resistant prostate cancer (CRPC). The SARD is a previously reported N -carboxy-cyanotrifluoromethylaniline analog that binds...
20:45 , Apr 28, 2017 |  BC Extra  |  Financial News

Epic raises $40M in series D

Liquid biopsy company Epic Sciences Inc. (La Jolla, Calif.) raised $40 million in a series D financing led by Hermed Capital. Also participating were Altos Capital Partners, Domain Associates, Genomic Health Inc. (NASDAQ:GHDX), Pagoda Investment,...
07:00 , Aug 1, 2016 |  BC Week In Review  |  Clinical News

Galeterone: Phase III discontinued

Tokai discontinued the open-label, international Phase III ARMOR3-SV trial in about 148 treatment-naive metastatic CRPC patients whose tumors express androgen receptor splice variant 7 (AR- V7 ) after an analysis by an IDMC showed that...
07:00 , Jul 26, 2016 |  BC Extra  |  Clinical News

Tokai ending galeterone study

Tokai Pharmaceuticals Inc. (NASDAQ:TKAI) fell $4.10 (79%) to $1.10 on Tuesday after it said it would stop the Phase III ARMOR3-SV study of galeterone ( TOK-001 ) to treat metastatic castration-resistant prostate cancer (CRPC). Tokai...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Clinical News

Galeterone: Phase III started

Tokai began the open-label, international Phase III ARMOR3-SV trial to compare 2,550 mg oral galeterone once daily vs. once-daily oral Xtandi enzalutamide in 148 treatment-naive patients whose tumors express androgen receptor splice variant 7 (AR-...